Eunika Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 8 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 M
- Revenue Growth 25.69%
- Profit Growth 46.47%
- Ebitda 30.23%
- Net Worth 21.83%
- Total Assets 66.34%
About Eunika Therapeutics
Eunika Therapeutics Private Limited (ETPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 September 2016 (Eight years and four months 26 days old ). Its registered office is in Patna, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹2.50 M.
Brij Prasad, Mukesh Raj, Anil Kumar, and One other member serve as directors at the Company.
Company Details
-
Location
Patna, Bihar, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51900BR2016PTC032522
-
Company No.
032522
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Sep 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Eunika Therapeutics?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajat Dutta
|
Director | 14-Sep-2016 | Current |
|
Anil Kumar
|
Director | 14-Sep-2016 | Current |
|
Brij Prasad
|
Director | 14-Sep-2016 | Current |
|
Mukesh Raj
|
Director | 14-Sep-2016 | Current |
Financial Performance of Eunika Therapeutics.
Eunika Therapeutics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 25.69% increase. The company also saw a substantial improvement in profitability, with a 46.47% increase in profit. The company's net worth Soared by an impressive increase of 21.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eunika Therapeutics?
Unlock access to Eunika Therapeutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹2.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Apr 2022 | Others | ₹2.50 M | Open |
How Many Employees Work at Eunika Therapeutics?
Eunika Therapeutics has a workforce of 33 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eunika Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eunika Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.